MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2019-09-09
Last Posted Date
2019-09-09
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Target Recruit Count
31
Registration Number
NCT04081844
Locations
🇰🇷

Korea University Hospital (Anam), Seoul, Korea, Republic of

Chinese Medicine Treat for Hypertensive Renal Injury

Phase 2
Conditions
Renal Injury
Hypertension
Interventions
Drug: Qianyangyuyin 20g Granule
Drug: placebo
First Posted Date
2019-09-06
Last Posted Date
2019-09-06
Lead Sponsor
Jiangsu Province Hospital of Traditional Chinese Medicine
Target Recruit Count
520
Registration Number
NCT04078711

A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia

Phase 3
Completed
Conditions
Hypertension
Dyslipidemias
Interventions
First Posted Date
2019-08-30
Last Posted Date
2020-11-30
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Target Recruit Count
145
Registration Number
NCT04074551
Locations
🇰🇷

Seoul National University Hospital, Seoul, Seoul-si, Korea, Republic of

Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes

Phase 4
Withdrawn
Conditions
Diabetes Mellitus
Hypertension
Interventions
Drug: Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET
Drug: Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET
First Posted Date
2019-06-07
Last Posted Date
2020-09-03
Lead Sponsor
The University of The West Indies
Registration Number
NCT03978884
Locations
🇯🇲

Tropical Metabolism Research Unit, Kingston, Other, Jamaica

Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Peritoneal Dialysis Patients

Phase 4
Conditions
End Stage Renal Disease
Peritoneal Dialysis
Interventions
First Posted Date
2019-05-17
Last Posted Date
2019-09-04
Lead Sponsor
Chiang Mai University
Target Recruit Count
84
Registration Number
NCT03953950
Locations
🇹🇭

Pharmacoepidemiology and Statistics Research Center, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand

Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study

Phase 2
Conditions
Glioblastoma
Brain Metastases
Interventions
First Posted Date
2019-05-15
Last Posted Date
2023-11-01
Lead Sponsor
Kyrre Eeg Emblem
Target Recruit Count
165
Registration Number
NCT03951142
Locations
🇳🇴

Oslo University Hospital, Oslo, Norway

The Pharmacokinetic Interaction Between Amlodipine and Losartan

First Posted Date
2019-04-11
Last Posted Date
2019-04-12
Lead Sponsor
Korea University Anam Hospital
Target Recruit Count
24
Registration Number
NCT03912285
Locations
🇰🇷

Dept. of Clinical Pharmacology & Toxicology, Anam Hospital, Korea University College of Medicine, Seoul, Korea, Republic of

Losartan + Sunitinib in Treatment of Osteosarcoma

Phase 1
Recruiting
Conditions
Osteosarcoma
Interventions
First Posted Date
2019-04-03
Last Posted Date
2025-02-24
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
41
Registration Number
NCT03900793
Locations
🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

and more 1 locations

A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

Phase 2
Completed
Conditions
Hypertension
Interventions
First Posted Date
2019-04-01
Last Posted Date
2022-07-14
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Target Recruit Count
248
Registration Number
NCT03897868
Locations
🇰🇷

Donggguk University Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath